HCW lowers Capricor Therapeutics PT to $9

Capricor Therapeutics

H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17.

Analyst Joseph Pantginis writes that after meeting with management, “our key takeaway is that 2020 represents a company-defining year,” with its lead drug candidate, CAP-1002 for the treatment of Duchenne muscular dystrophy.

He said 12-month data from the HOPE-2, likely within the next couple of months, should be the most critical event for the company assessing efficacy and durability at longer-term follow-up.

“These data are likely to define whether CAP-1002 moves forward to a pivotal HOPE-3 study,” he said. Management has been in active dialog with the FDA to define next steps and the upcoming 12-month data “should drive final feedback from the agency,” he added.

“Should a path forward for CAP-1002 be defined, HOPE-3 is projected to cost approximately $15-million, which continues to drive the financing overhang at the company,” Mr. Pantginis said. “To this end, however, the company would potentially look to geographical partnerships as a source of non-dilutive funding.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.